Related Experiment Video
Updated: May 27, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms
Filippo Bellati1, Chiara Napoletano, Maria Luisa Gasparri
1Department of Gynaecology and Obstetrics, Sapienza University of Rome, Italy. filippo.bellati@uniroma1.it
Critical Reviews in Oncology/Hematology
|November 8, 2011
Summary
Bevacizumab, a monoclonal antibody targeting Vascular Endothelial Growth Factor (VEGF), shows promise in treating gynecological cancers by inhibiting tumor angiogenesis. It offers improved outcomes with tolerable side effects compared to traditional chemotherapy.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Gynecological malignancies have seen improved outcomes with combination drug therapy over 50 years, yet results remain unsatisfactory for advanced or recurrent diseases.
- New therapeutic strategies are urgently needed due to limited long-term responses with current treatments.
- Monoclonal antibodies (MoAb) targeting Vascular Endothelial Growth Factor (VEGF) represent a promising new therapeutic avenue.
Purpose of the Study:
- To review the rationale for investigating anti-angiogenetic compounds like Bevacizumab.
- To summarize clinical evidence for Bevacizumab in treating gynecological malignancies.
- To focus on the potential benefits and adverse effects of Bevacizumab.
Main Methods:
- Review of existing and emerging clinical evidence on Bevacizumab in gynecological cancers.
- Analysis of Bevacizumab's mechanism of action in inhibiting tumor angiogenesis via VEGF blockade.
- Evaluation of clinical trial data regarding efficacy, safety, and combination therapy.
Main Results:
- Bevacizumab targets VEGF, a key factor in tumor angiogenesis, essential for tumor growth and progression.
- Clinical trials demonstrate successful use of Bevacizumab, alone or in combination, in gynecological cancers.
- Adverse reactions are generally tolerable and less significant than conventional chemotherapy, allowing combination with cytotoxic drugs.
Conclusions:
- Bevacizumab is a promising anti-angiogenetic agent for gynecological malignancies.
- Its favorable toxicity profile supports combination therapy with chemotherapy.
- Further research and clinical application of Bevacizumab are warranted for improved patient outcomes.
Related Concept Videos
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...